AKBA

Akebia Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 12:40 UTC

Last close

0.43USD

Market data, 2026-11-05

Except where said otherwise: 10-K for 2025, filed 2026-02-26

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001517022-26-000020
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001517022-26-000020
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
The filing itself
-2.3%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001517022-26-000020
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
28.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001517022-26-000020
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
1.59Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001517022-26-000020
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.24 against 0.58 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.12x

0.04x

-0.85x

0.65x

0.09x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-05

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales1.12x
Its own average over 10 years, 211.5M.
Profit0.04x
Its own average over 10 years, -152.0M.
Free cash flow-0.85x
Its own average over 10 years, -79.9M.
Debt0.65x
Its own average over 8 years, 79.1M.
Price0.09x
Its own average over 11 years, 5. Market data, 2026-11-05

Free cash flow is furthest from its own average, at -0.85 times.

Sales is 1.12 times its own 10-year average; Profit is 0.04 times its own 10-year average; Free cash flow is -0.85 times its own 10-year average; Debt is 0.65 times its own 8-year average; Price is 0.09 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales against its own 10-year average1.12
Source
filed
Statement
income
Fiscal year
2025
Accession
0001517022-26-000020
Reported in
USD
The filing itself
Profit against its own 10-year average0.04
Source
filed
Statement
income
Fiscal year
2025
Accession
0001517022-26-000020
Reported in
USD
The filing itself
Free cash flow against its own 10-year average-0.85
Source
filed
Statement
income
Fiscal year
2025
Accession
0001517022-26-000020
Reported in
USD
The filing itself
Debt against its own 8-year average0.65
Source
filed
Statement
income
Fiscal year
2025
Accession
0001517022-26-000020
Reported in
USD
The filing itself
Price against its own 11-year average0.09Market data, 2026-11-05
Source
market
Taken on
2026-11-05
Reported in
USD